肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2011年
3期
179-181
,共3页
侯瑞鹏%张廷继%朱广博%王小波
侯瑞鵬%張廷繼%硃廣博%王小波
후서붕%장정계%주엄박%왕소파
膀胱肿瘤%肝细胞生长因子%核基质相关蛋白质类
膀胱腫瘤%肝細胞生長因子%覈基質相關蛋白質類
방광종류%간세포생장인자%핵기질상관단백질류
Urinary bladder neoplasms%Hepatocyte growth factor%,Nuclear matrix-associated proteins
目的 探讨膀胱尿路上皮癌患者尿中肝细胞生长因子(HGF)和核基质蛋白22(NMP22)表达水平与膀胱尿路上皮癌分期和分级的关系.方法 膀胱移行细胞癌(TCC)接受保留膀胱手术的患者48例,均采用吡柔比星(THP)膀胱灌注.采用酶联免疫吸附法(ELISA)分别检测灌注前、灌注后6个月尿中HGF和NMP22的含量.结果 术后12个月复发率为12.5%(6/48).灌注前尿HGF水平随肿瘤的分级、分期升高而增加,各级或期间HGF水平差异均有统计学意义(P＜0.05),NMP22含量随肿瘤分期升高而增加,各期间差异均有统计学意义(均P＜0.05).HGF、NMP22和尿细胞学检测对膀胱尿路上皮癌术后复发的敏感度分别为100%(6/6)、83.3%(5/6)和66.7%(4/6);特异度分别为61.9%(26/42)、57.1%(24/42)和97.6%(41/42).结论 HGF和NMP22均为膀胱尿路上皮癌患者尿中良好肿瘤标志物,与肿瘤的分期和分级密切相关,结合尿细胞学检测可以作为膀胱尿路上皮癌早期筛查和诊断的有效指标.
目的 探討膀胱尿路上皮癌患者尿中肝細胞生長因子(HGF)和覈基質蛋白22(NMP22)錶達水平與膀胱尿路上皮癌分期和分級的關繫.方法 膀胱移行細胞癌(TCC)接受保留膀胱手術的患者48例,均採用吡柔比星(THP)膀胱灌註.採用酶聯免疫吸附法(ELISA)分彆檢測灌註前、灌註後6箇月尿中HGF和NMP22的含量.結果 術後12箇月複髮率為12.5%(6/48).灌註前尿HGF水平隨腫瘤的分級、分期升高而增加,各級或期間HGF水平差異均有統計學意義(P＜0.05),NMP22含量隨腫瘤分期升高而增加,各期間差異均有統計學意義(均P＜0.05).HGF、NMP22和尿細胞學檢測對膀胱尿路上皮癌術後複髮的敏感度分彆為100%(6/6)、83.3%(5/6)和66.7%(4/6);特異度分彆為61.9%(26/42)、57.1%(24/42)和97.6%(41/42).結論 HGF和NMP22均為膀胱尿路上皮癌患者尿中良好腫瘤標誌物,與腫瘤的分期和分級密切相關,結閤尿細胞學檢測可以作為膀胱尿路上皮癌早期篩查和診斷的有效指標.
목적 탐토방광뇨로상피암환자뇨중간세포생장인자(HGF)화핵기질단백22(NMP22)표체수평여방광뇨로상피암분기화분급적관계.방법 방광이행세포암(TCC)접수보류방광수술적환자48례,균채용필유비성(THP)방광관주.채용매련면역흡부법(ELISA)분별검측관주전、관주후6개월뇨중HGF화NMP22적함량.결과 술후12개월복발솔위12.5%(6/48).관주전뇨HGF수평수종류적분급、분기승고이증가,각급혹기간HGF수평차이균유통계학의의(P＜0.05),NMP22함량수종류분기승고이증가,각기간차이균유통계학의의(균P＜0.05).HGF、NMP22화뇨세포학검측대방광뇨로상피암술후복발적민감도분별위100%(6/6)、83.3%(5/6)화66.7%(4/6);특이도분별위61.9%(26/42)、57.1%(24/42)화97.6%(41/42).결론 HGF화NMP22균위방광뇨로상피암환자뇨중량호종류표지물,여종류적분기화분급밀절상관,결합뇨세포학검측가이작위방광뇨로상피암조기사사화진단적유효지표.
Objective To evaluate the relationship of the hepatocyte growth factor (HGF) and the nuclear matrix protein 22 (NMP22) in urine and the stage and grade of bladder uroepithelium carcinoma.Methods A total of 48 post-operative patients (males 39, females 9) with bladder cancer enrolled in this study were perfused with THP. The voided urine of all the patients before and 6 months after perfusion were recovered selectively. HGF and NMP22 ELISA kits were used to detect bladder cancer. Results The recurrence rate was 12.5 %. The HGF level had positive correlation with the stage and grade of bladder uroepithelium carcinoma (P ＜0.05). The NMP22 level had positive correlation with the grade of bladder cancer. The sensitivity and specificity of HGF, NMP22 and cytology were 100 % (6/6), 83.3 % (5/6), 66.7 %(4/6) and 61.9 % (26/42), 57.1% (24/42), 97.6 % (41/42), respectively. Conclusion The HGF and NMP22 are both valuable tumor markers in the urine of bladder uroepithelium carcinoma. They have intimate relation with the stage and grade of bladder uroepithelium carcinoma. Hence combined with cytology, they could be selected as the significance level of early screening and diagnosing.
